fbpx

GlaxoSmithKline Pharmaceuticals Ltd

GLAX.NS

$24.15

Closing

▼-0.96%

1D

▼-7.29%

YTD

GLAX

BBG001S83CX3

Exchange

Sector

Market cap

$4.09B

Volume

241,306

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$4.09B

Analysts' Rating

BUY

Price Target (Mean)

34.67

Total Analysts

4

P/E

52.71

Operating Margin

24.29%

Beta

0.47

Revenue Growth

5.62%

52 week high

$35.57

52 week low

$21.22

Div. Yield

1.53%

EPS Growth

0.00

Company Profile

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company’s general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company’s vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.